Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
The EMBO Journal|October 17, 2023
Hematopoietic stem cells undergo a lymphoid to myeloid switch in early stages of emergency granulopoiesisKarolina Vanickova, Mirko Milosevic, Irina Ribeiro Bas, et al.
Cancer Letters|March 9, 2010
A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitroEri Kawata, Eishi Ashihara, Yoko Nakagawa, et al.
Blood Advances|February 14, 2019
C/EBPβ is a critical mediator of IFN-α-induced exhaustion of chronic myeloid leukemia stem cellsAsumi Yokota, Hideyo Hirai, Ryuichi Sato, et al.
European Journal of Immunology|December 25, 2010
Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosisKazuki Sakai, Eri Kawata, Eishi Ashihara, et al.
The American Journal of Chinese Medicine|March 1, 2021
Arsenic Dispensing Powder Promotes Erythropoiesis in Myelodysplastic Syndromes via Downregulation of HIF1A and Upregulation of GATA FactorsTeng Fan, Xiaomin Feng, Asumi Yokota, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse modelEishi Ashihara, Eri Kawata, Yoko Nakagawa, et al.
British Journal of Haematology|November 22, 2007
ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanismsJunya Kuroda, Shinya Kimura, Michael Andreeff, et al.
Blood|September 7, 2006
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activityAsumi Yokota, Shinya Kimura, Satohiro Masuda, et al.
Leukemia Research|March 11, 2008
Fully automated and super-rapid system for the detection of JAK2V617F mutationRuriko Tanaka, Junya Kuroda, William Stevenson, et al.
Blood|June 16, 2010
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cellsRuriko Tanaka, Matthew S Squires, Shinya Kimura, et al.
Pageof 4